DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT05746039

RecruitingPhase 1, PHASE2

Feasibility of Semaglutide in Advanced Lung Disease

Feasibility of Semaglutide Therapy for Weight Loss in Advanced Lung Disease: A Pilot Study

Asset

Semaglutide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

1

Enrollment

8

estimated

Study population

Obesity / overweight, Pulmonary Disease, Chronic Obstructive

Key I/E criterion

•BMI ≥30

Primary endpoint

•Tolerability

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT05746039
Org study ID852967

Timeline

Milestones

Study first posted2023-02-27actual
Study start2024-01-29actual
Last update posted2026-04-21actual
Primary completion2027-12-28estimated
Study completion2027-12-28estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweightPulmonary Disease, Chronic Obstructive

Eligibility

Who can enroll

Minimum age18 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Diagnosis of one of the following lung diseases: interstitial lung disease, sarcoidosis, chronic obstructive pulmonary disease, or pulmonary hypertension
•Age > 18
•BMI > 30 kg/m2
•Requires supplemental oxygen on exertion
•Stable treatment regimen X 90 days
•Use of disease-modifying therapy

Exclusion criteria

•Diabetes
•Pregnant or Breastfeeding
•Recent weight loss
•Recent or chronic GI complaints
•History of gastroparesis
•History of scleroderma
•Hospitalized at time of evaluation
•Use of weight loss medication in last 90 days
•Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia (type 2)
•Uncontrolled thyroid disease
•History of acute/chronic pancreatitis
•Prior suicide attempt
•Suicidal ideation in last 90 days
•Presence of a pacemaker or defibrillator

Endpoints (12)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes
4
Weight & body composition
3
Cardiometabolic biomarkers
2
Glycemic / diabetes
1
Heart failure
1
Safety / tolerability / PK
1

Weight & body composition

3 endpoints
Secondary/protocol endpoint

Body composition

Time frame:Baseline to 12 weeks

Total fat mass

percent change from baseline, improvement

Secondary/protocol endpoint

Body composition

Time frame:Baseline to 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Body composition

Time frame:Baseline to 12 weeks

Body weight, absolute change (kg)

change from baseline, improvement

Glycemic / diabetes

1 endpoint
Secondary/protocol endpoint

Markers of adiposity and insulin resistance

Time frame:Baseline to 12 weeks

HbA1c, change

change from baseline, improvement

LOINC 4548-4

Heart failure

1 endpoint
Secondary/protocol endpoint

Physical function

Time frame:Baseline to 12 weeks

6-minute walk distance

change from baseline, improvement

Cardiometabolic biomarkers

2 endpoints
Secondary/protocol endpoint

Markers of adiposity and insulin resistance

Time frame:Baseline to 12 weeks

hs-CRP, change

change from baseline, improvement

LOINC 30522-7

Secondary/protocol endpoint

Markers of adiposity and insulin resistance

Time frame:Baseline to 12 weeks

Free fatty acids, change

change from baseline, improvement

Safety / tolerability / PK

1 endpoint
Primary/protocol endpoint/low confidence

Tolerability

Time frame:12 weeks

threshold achievement, descriptive

Other clinical outcomes

4 endpoints
Secondary/protocol endpoint

Lung function

Time frame:Baseline to 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Lung function

Time frame:Baseline to 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Lung function

Time frame:Baseline to 12 weeks

change from baseline, improvement

Secondary/protocol endpoint

Physical function

Time frame:Baseline to 12 weeks

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.